The company holds a patent for a gene delivery process called adeno-associated virus (AAV).
AAV utilizes the natural ability of the virus to transmit genetic material into cells, thus serving as a carrier for carrying therapeutic genes into human cells. In addition, this biotechnology company also has a pending CMV patent, which is a gene delivery method that can support larger genetic loads due to its larger genome size and unique ability to integrate multiple genes. Therefore, CMV minimizes the number of treatments required as it can transmit more genetic information at once. In the initial animal studies, CMV treatment was believed to extend lifespan by more than 41%. It has been proved to be an effective delivery vector, and has been used as part of a variety of immunotherapies, including cancer, AIDS and malaria treatment.

The vulnerability of the elderly population is mainly due to their immune system being in a cellular aging state, where cells no longer divide and self repair; This is due to the result of telomere shortening

-It can be compared to a shoelace cap located at the end of our DNA strand
-This inevitably accompanies biological aging< br> -This damage is related to diseases such as osteoporosis, heart disease, dementia, Alzheimer's disease, and cancer< br>